Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs - News-Medical.net

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting MabsNews-Medical.netBiopharmaceutical immuno-oncology company Stem Cell Therapeutics (SCT) has entered an agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein (CD172a). This technology was Stem Cell Therapeutics Strengthens CD47 Franchise With Acquistion of Stockhouse all 4 news articles read more

http://blog.zandcell.com/stem-cell-therapeutics-nabs-sirpa-protein-targeting-mabs-news-medical-net/?utm_source=rss&utm_medium=rss&utm_campaign=stem-cell-therapeutics-nabs-sirpa-protein-targeting-mabs-news-medical-net